PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry [PDF]
npj Breast CancerGermline BRCA1 and BRCA2 mutations enable targeted therapies in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). The two poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors olaparib and talazoparib were ...
Manuel Hörner +52 more
doaj +2 more sources
Canadian Journal of Health TechnologiesReimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception ...
europepmc +2 more sources
Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program [PDF]
BMC CancerIntroduction Talazoparib is a strong PARP inhibitor with significant catalytic inhibition as well as the ability to cause PARP entrapment at DNA damage sites. It is one of the recommended treatments for individuals with BRCA-mutant advanced breast cancer,
Mehmet Ali Nahit Sendur +41 more
doaj +2 more sources
Frontiers in Oncology, 2019 Talazoparib, a potent PARP inhibitor, induces synthetic lethality in BRCA-deficient cancers making it an attractive candidate for ovarian cancer treatment.
Paige Baldwin +2 more
exaly +3 more sources
Cost-effectiveness of talazoparib plus enzalutamide as first-line therapy in metastatic castration-resistant prostate cancer [PDF]
Therapeutic Advances in Medical OncologyBackground: The phase III TALAPRO-2 trial established that combining talazoparib (TALA) with enzalutamide significantly extends progression-free survival (PFS) and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients ...
Jiaming Zhu +3 more
doaj +2 more sources
Detection and analysis of the safety profile of talazoparib based on FAERS database
Expert Opinion on Drug SafetyTalazoparib was approved for the treatment of breast cancer. However, the safety of talazoparib in a large population sample over an extended period remained uncertain. The objective of this study is to offer guidance for the secure utilization of talazoparib in clinical settings.
Yang Li
exaly +3 more sources
Limitations of Subgroup Safety Analyses for Drug-Drug Interaction Evaluation: Insights from the Talazoparib P-gp Inhibitor Case. [PDF]
J Clin PharmacolAbstract Impact of concomitant medications (conmeds) on the safety of the investigational agent is often evaluated using subgroup analyses for safety events in patients who received the conmed versus those who did not. Here, we highlight the potential biases and inconclusive results that can arise from such analyses, using talazoparib and P ...
Wang D +4 more
europepmc +2 more sources
Talazoparib and radiation enhance the senolytic efficacy of venetoclax in therapy-induced senescent triple-negative breast cancer cells [PDF]
Saudi Pharmaceutical JournalTriple-negative breast cancer (TNBC) presents ongoing clinical challenges, often leading to relapse in many patients. The relapse is partly explained by tumor cells transitioning into a senescent state following chemotherapy or radiation, resulting in a ...
Sultan Almudimeegh +9 more
doaj +2 more sources
A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer. [PDF]
CancerAbstract Background Poly(adenosine diphosphate ribose) polymerase (PARP) is recruited to DNA damage sites along with epigenetic factors such as DNA methyltransferase 1 (DNMT1). Inhibitors of DNMT modulate reactive oxygen species (ROS)‐cyclic adenosine monophosphate (cAMP)/Protein Kinase A signaling and induce a “BRCAness phenotype” that further ...
Miller KD +14 more
europepmc +2 more sources
A Design of Experiments-Based Chiral HPLC Method for the Quantification of Talazoparib and Enantiomeric Purity Determination in Pharmaceutical Formulations. [PDF]
ChiralityA design of experiments–based chiral HPLC method was developed for the enantiomeric separation and quantification of talazoparib in pharmaceutical formulations. Efficient resolution of the enantiomers (RS > 7) was achieved within 12 min. The method was validated and successfully applied to tablet analysis, and its environmental sustainability was ...
Atila Karaca S, Aliyeva S, Yeniceli D.
europepmc +2 more sources